Answers are grounded in this paper and cite their sources.
Investigates CDKN3 regulation in breast cancer therapies, suggesting potential therapeutic targets.
The cyclin-dependent kinase inhibitor 3, CDKN3, is a dual-specificity phosphatase studied for its implications in human malignancies as both an oncogene and tumor suppressor. While the role of CDKN3 as a negative regulator of the cell cycle through its inactivation of CDK1/2 is well-documented, little is known about additional CDKN3 substrates that may play a role in cell cycle regulation. Furthermore, targeted protein degradation by the ubiquitin-proteasome system, UPS, is an essential cell cycle regulating mechanism for cellular division; however, there is very limited knowledge about the proteins involved in the ubiquitin cascade that regulates CDKN3 degradation. Thus, this study aims to investigate the regulation of CDKN3 in response to Palbociclib—a clinically approved CDK4/6 inhibitor administered to patients with HR+/HER2- breast cancer—to further understand the role of CDKN3 in cell cycle progression and tumorigenesis in human breast cancer. Using multiple cancerous and noncancerous cell lines, cells were treated with CDK4/6 inhibitors to promote a G1 cellular arrest and immunoblot analysis was performed to observe changes in CDKN3 abundance. Our findings demonstrate CDK4/6 inhibition decreases the abundance of CDKN3 by promoting its degradation. Additionally, drugs targeting various parts of the UPS reveal inhibition of the proteasome rescues CDKN3 after CDK4/6 inhibition. Lastly, using mass spectrometry analysis we identified a list of CDKN3 interactors. Defining the mechanisms behind CDKN3 regulation is important to understanding the biological significance of CDKN3 degradation following CDK4/6 inhibition. Although the exact function of CDKN3 in the tumorigenesis of breast cancer remains to be elucidated, these findings highlight the importance of CDKN3—or a novel CDKN3 phospho-substrate—as a potential biomarker or therapeutic target in the treatment of HR+/HER2- breast cancer.
No takes yet. Share an insight, caveat, or question.
Sarah Whittington (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: